Breast Cancer Gene Case Has Another Day in Court
By Eric Hoffman and Jaydee Hanson, Biopolitical Times guest contributors
| 04. 07. 2011
A three-judge federal appeals court heard arguments on Monday in a
case that could decide the future of human gene patents. The
high-profile lawsuit was filed by the American Civil Liberties Union and
the Public Patent Foundation on behalf of a number of researchers,
patients, women’s health organizations and scientific organizations
against Myriad Genetics and the University of Utah Research Foundation,
holders of patents on genes known as BRCA1 and BRCA2 that are associated
with elevated risk of breast cancer. The plaintiffs argue that the US
Patent and Trade Office erred in granting these patents because genes
are products of nature, not human inventions.
The panel heard Myriad’s appeal of a decision strongly favoring the
plaintiffs that was issued in March 2010 by Federal District Court Judge
Robert Sweet. Whatever is decided by the appeals court, many observers
expect the case to continue on to the Supreme Court.
A few things stood out in Monday’s hearing. First, the judges were very
interested in whether all the plaintiffs actually have standing in the
case – that is, in whether they have...
Related Articles
By Anumita Kaur [cites CGS’ Katie Hasson], The Washington Post | 03.25.2025
Genetic information company 23andMe has said that it is headed to bankruptcy court, raising questions for what happens to the DNA shared by millions of people with the company via saliva test kits.
Sunday’s announcement clears the way for a new...
By Peter Wehling, Tino Plümecke, and Isabelle Bartram
| 03.26.2025
This article was originally published as “Soziogenomik und polygene Scores” in issue 272 (February 2025) of the German-language journal Gen-ethischer Informationsdienst (GID); translated by the authors.
In mid-November 2024, the British organization Hope not Hate published its investigative research ‘Inside the Eugenics Revival’. In addition to documentating an active international “race research” network, the investigation also brought to light the existence of a US start-up that offers eugenic embryo selection. Heliospect Genomics aims to enable wealthy couples to...
By Frank Landymore, Futurism | 03.18.2025
You can only throw so much money at a problem.
This, more or less, is the line being taken by AI researchers in a recent survey. Asked whether "scaling up" current AI approaches could lead to achieving artificial general...
By Craig S. Smith, Forbes | 03.08.2025
One recent evening in Shenzhen, a group of software engineers gathered in a dimly lit co-working space, furiously typing as they monitored the performance of a new AI system. The air was electric, thick with the hum of servers and...
